1,24-dihydroxycholecalciferol | 61616-90-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 1,24-dihydroxycholecalciferol
• 英文别名: (1R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• CAS: 61616-90-8
• 化学式: C₂₇H₄₄O₃
• 分子量: 416.645
• InChiKey: BJYLYJCXYAMOFT-XAHYHXPISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] LAULIMALIDE DERIVATIVES<br/>[FR] DERIVES LAULIMALIDE
  申请人：KOSAN BIOSCIENCES INC

  公开号：WO2002064589A1

  公开（公告）日：2002-08-22

  Laulimalide compounds, intermediates thereto and methods for their preparation and methods for their use in the treatment of diseases characterized by cellular hyperproliferation. Formula (I).

  Laulimalide化合物，其中间体及其制备方法以及其在治疗细胞过度增殖所导致的疾病中的应用方法。公式(I)。
• Laulimalide Analogs and Uses Thereof
  申请人：Gallagher Jr M. Brian

  公开号：US20070287745A1

  公开（公告）日：2007-12-13

  The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 10 , q, t, X 0 , X 1 , A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

  本发明提供具有公式I的化合物及其药学上可接受的衍生物，其中R1-R10、q、t、X0、X1、A、B、D、E、G、J、K、L、M和Z如本文中一般和在类别和子类别中所述，并且此外还提供其药物组合物以及使用它们治疗与细胞过度增殖相关的疾病的方法。
• Oral sustained release pharmaceutical preparation
  申请人：TEIJIN LIMITED

  公开号：EP0205336A2

  公开（公告）日：1986-12-17

  This invention is concerned with an oral sustained release pharmaceutical preparation which is prepared as a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs, or a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs together with a foaming agent, so that it may release the active drugs by such slow degrees in the stomach or the intestinal tract as to make it possible to provide an adequate supply of active drugs in enough concentration to display their therapeutic value for many hours.

  本发明涉及一种口服缓释药物制剂，它是由纤维素低级烷基醚、聚丙烯酸或其药学上可接受的盐和活性药物组成的药物制剂，或者是由纤维素低级烷基醚、聚丙烯酸或其药学上可接受的盐和活性药物与发泡剂组成的药物制剂，这样它就可以在胃或肠道中缓慢释放活性药物，从而可以提供足够浓度的活性药物，使其在多个小时内显示出治疗价值。
• Compositions for topical treatment of psoriasis and atopic dermatitis
  申请人：TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0544391A1

  公开（公告）日：1993-06-02

  Use of a compound selected from the group consisting of pentoxifylline, propentofylline and torbafylline for topical treatment of psoriasis or atopic dermatitis and pharmaceutical compositions comprising them.

  选自喷托非瑞林、丙托非瑞林和托巴非瑞林的化合物用于局部治疗银屑病或特应性皮炎的用途，以及包含它们的药物组合物。
• Laulimalide derivatives
  申请人：——

  公开号：US20020128471A1

  公开（公告）日：2002-09-12

  Laulimalide compounds, intermediates thereto and methods for their preparation, and methods for their use in the treatment of diseases characterized by cellular hyperproliferation. 1

  Laulimalide 化合物、其中间体及其制备方法，以及用于治疗以细胞过度增殖为特征的疾病的方法。 1